Supplementary Figure S1 from Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial

Study Schema. This is a single-arm, phase II trial combining durvalumab and cetuximab in patients with recurrent/metastatic HNSCC. Patients received the loading dose of cetuximab followed by the addition of durvalumab with weekly cetuximab doses. CT scans were done every eight weeks. Blood draws for correlatives occurred at screening, after the loading dose of cetuximab, and after the first dose of durvalumab and cetuximab combined.Abbreviations: CT, computed tomography; POD, progression of disease